Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
40 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Sareum Holdings Plc - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Sareum Holdings plc - Product Pipeline Review - 2015', provides an overview of the Sareum Holdings plc's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Sareum Holdings plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Sareum Holdings plc including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Sareum Holdings plc's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Sareum Holdings plc's pipeline products Reasons To Buy - Evaluate Sareum Holdings plc's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Sareum Holdings plc in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Sareum Holdings plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Sareum Holdings plc and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sareum Holdings plc - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Sareum Holdings plc and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Sareum Holdings Plc Snapshot 5 Sareum Holdings Plc Overview 5 Key Information 5 Key Facts 5 Sareum Holdings Plc - Research and Development Overview 6 Key Therapeutic Areas 6 Sareum Holdings Plc - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Sareum Holdings Plc - Pipeline Products Glance 11 Sareum Holdings Plc - Early Stage Pipeline Products 11 Preclinical Products/Combination Treatment Modalities 11 Discovery Products/Combination Treatment Modalities 12 Sareum Holdings Plc - Drug Profiles 13 CCT-244747 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 CCT-245737 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 SAR-020106 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 SAR-20347 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 SAR-3 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 SAR-4 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 SART-1 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 SART-29 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 SART-33 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Small Molecules to Antagonize VEGFR-3 for Oncology 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Small Molecules to Inhibit B-RAF Kinase for Oncology 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Small Molecules to Inhibit Polo-Like Kinase-1 for Oncology 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Sareum Holdings Plc - Pipeline Analysis 29 Sareum Holdings Plc - Pipeline Products by Target 29 Sareum Holdings Plc - Pipeline Products by Route of Administration 30 Sareum Holdings Plc - Pipeline Products by Molecule Type 31 Sareum Holdings Plc - Pipeline Products by Mechanism of Action 32 Sareum Holdings Plc - Recent Pipeline Updates 33 Sareum Holdings Plc - Dormant Projects 35 Sareum Holdings Plc - Company Statement 36 Sareum Holdings Plc - Locations And Subsidiaries 38 Head Office 38 Other Locations & Subsidiaries 38 Appendix 39 Methodology 39 Coverage 39 Secondary Research 39 Primary Research 39 Expert Panel Validation 39 Contact Us 39 Disclaimer 40
List of Tables
Sareum Holdings Plc, Key Information 5 Sareum Holdings Plc, Key Facts 5 Sareum Holdings Plc - Pipeline by Indication, 2015 7 Sareum Holdings Plc - Pipeline by Stage of Development, 2015 9 Sareum Holdings Plc - Monotherapy Products in Pipeline, 2015 10 Sareum Holdings Plc - Preclinical, 2015 11 Sareum Holdings Plc - Discovery, 2015 12 Sareum Holdings Plc - Pipeline by Target, 2015 29 Sareum Holdings Plc - Pipeline by Route of Administration, 2015 30 Sareum Holdings Plc - Pipeline by Molecule Type, 2015 31 Sareum Holdings Plc - Pipeline Products by Mechanism of Action, 2015 32 Sareum Holdings Plc - Recent Pipeline Updates, 2015 33 Sareum Holdings Plc - Dormant Developmental Projects,2015 35 Sareum Holdings Plc, Subsidiaries 38
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.